Home/Pipeline/HD mAb Therapy

HD mAb Therapy

Huntington's Disease

Pre-clinicalActive

Key Facts

Indication

Huntington's Disease

Phase

Pre-clinical

Status

Active

Company

HD Immune

About HD Immune

HD Immune is a private, preclinical-stage biotech developing a monoclonal antibody therapy for Huntington's disease. Its approach targets extracellular mutant huntingtin protein to block its intercellular transmission and spread of pathology, aiming to slow disease progression. The company leverages proprietary knowledge and published research from its founder, Dr. Stefan Bartl, and maintains international research collaborations. As a pre-revenue entity, its primary focus is on optimizing its lead candidate for future human clinical trials.

View full company profile

Therapeutic Areas

Neurology Neurodegenerative Diseases

Other Huntington's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
Huntington's Disease Program	Rumi Scientific	Pre-clinical	Active
SOM3355	SOM Biotech	Phase 3	Active
LETI-101	ElevateBio	Preclinical	Active
Somatic Expansion Inhibitor Program	LoQus23 Therapeutics	Preclinical	Active
Preclinical Program	Excision BioTherapeutics	Preclinical	Active
NA-841	Biomed	Phase 2A	Active
T3D-959 (Future)	T3D Therapeutics	Pre-clinical / Research	Active
TT-P34	Teitur Trophics	Pre-clinical	Active
INT41	Vybion	Pre-clinical	Active
Huntington's Program	reMYND	Pre-clinical	Active
Pridopidine	Prilenia Therapeutics	Phase 3	Active